Ukraine's HIV epidemic, fueled primarily among opioid-dependent people who inject drugs (PWIDs), remains volatile despite gains achieved elsewhere. PWIDs account for ~70% of cumulative and >56% of new HIV infections. Despite Ukraine's HIV epidemic transition toward a generalized epidemic, empiric and mathematical modeling suggest that medication-assisted therapy (MAT) is the most effective and cost-effective approach to reverse this trend. MAT is associated with reduced HIV transmission and improved HIV treatment outcomes including engagement in care and antiretroviral medication access and adherence. Though MAT is free and capacity has increased from 120 to ~8,000 sub sized slots since 2004, <2% of PWIDs receive it. MAT scale-up is complex, poorly understood and has been fraught with low entry and high attrition. By 2011, only ~6100 slots remain filled - a number that has not increased appreciably in 12 months. Corrective interventions that facilitate MAT entry and retention are therefore crucial for HIV prevention and treatment efforts in Ukraine. We propose to improve MAT scale-up and build regional capacity in two distinct ways. In addition to examining client- and program-level facilitators and barriers to MAT, we will train and support Ukrainian experts in implementing an evidence-based and sustainable intervention, the Network for the Improvement of Addiction Treatment (NIATx) Model of Rapid Change Cycle, to improve MAT entry and retention. We will then evaluate the impact of the NIATx approach on MAT programs across Ukraine, using a pre/post intervention design to assess programmatic changes that promote MAT entry and retention. Second, we will create a new healthcare delivery model by integrating extended release naltrexone (XR-NTX) into HIV clinical care settings as a means to increase MAT access among HIV+ PWIDs. Administered only once-monthly, XR-NTX is a newly available and safe non-narcotic MAT that does not require narcological registration or have to be dispensed solely in licensed centers. Using implementation science techniques, we will examine both HIV (linkage to and retention in HIV care, initiation of and adherence with antiretroviral therapy) and substance abuse (time to opioid relapse, percent of days opioid free, retention on XR-NTX) treatment outcomes among an observational cohort of HIV+ PWIDs. The research and dissemination plan, consistent with PEPFAR's goals, expands sustainable treatment and prevention strategies and strengthens government partner relations by convening stakeholder meetings (e.g. Alliance Ukraine, Narcology and AIDS Center Directors, Ministry of Health, CDC, USAID, WHO, UNODC, Global Fund, Clinton Foundation, NGOs, etc) to facilitate NIATx implementation. By introducing evidence-based strategies and newly available medications that can forge new frontiers in HIV prevention and treatment, this project also builds local capacity and expertise in these innovative areas. Ukrainian HIV/AIDS programs also become better integrated and aligned with broader global health goals to improve health systems and maximize treatment capacity for multiple related and overlapping medical and psychiatric co-morbidities.

Public Health Relevance

Ukraine's explosive HIV epidemic, the most devastating in Europe, is primarily fueled by people who inject drugs (PWIDs). Despite medication-assisted therapy (MAT) being the most effective and cost-effective approach to reversing the epidemic, MAT scale-up in Ukraine has been hindered by poor MAT entry and retention. The proposed research identifies the barriers and facilitators to MAT, introduces an evidence-based intervention (NIATx) to promote sustainable MAT scale-up as well as innovatively introduces a new form of MAT, extended release naltrexone, to be integrated into HIV clinical care settings. This project meets PEPFAR's objectives to: 1) transition from an emergency response to HIV/AIDS to promotion of sustainable country programs; 2) strengthen partner government capacity to lead the response to this epidemic and other health demands; 3) expand prevention, care, and treatment in concentrated and generalized epidemics; 4) integrate and coordinate HIV/AIDS programs with broader global health and development programs to maximize impact on health systems; and 5) invest in innovation and operations research to evaluate existing programs, improve service delivery and maximize program outcomes.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
3R01DA033679-04S2
Application #
9038550
Study Section
Special Emphasis Panel (ZDA1)
Program Officer
Jones, Dionne
Project Start
2012-04-15
Project End
2016-03-31
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
4
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
Iakunchykova, Olena; Meteliuk, Anna; Zelenev, Alexei et al. (2018) Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine. Int J Drug Policy 57:11-17
Marcus, Ruthanne; Bojko, Martha J; Mazhnaya, Alyona et al. (2018) A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine. J Subst Abuse Treat 86:86-93
Zelenev, Alexei; Shea, Portia; Mazhnaya, Alyona et al. (2018) Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug Alcohol Depend 190:82-88
Stone, Jack; Fraser, Hannah; Lim, Aaron G et al. (2018) Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis 18:1397-1409
Rozanova, Julia; Morozova, Olga; Azbel, Lyuba et al. (2018) Perceptions of Health-Related Community Reentry Challenges among Incarcerated Drug Users in Azerbaijan, Kyrgyzstan, and Ukraine. J Urban Health 95:508-522
Makarenko, Iuliia; Mazhnaya, Alyona; Marcus, Ruthanne et al. (2018) Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine. J Subst Abuse Treat 87:1-8
Mazhnaya, Alyona; Meteliuk, Anna; Barnard, Tetiana et al. (2017) Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes. Int J Drug Policy 47:187-195
Hoff, Emily; Marcus, Ruthanne; Bojko, Martha J et al. (2017) The effects of opioid-agonist treatments on HIV risk and social stability: A mixed methods study of women with opioid use disorder in Ukraine. J Subst Abuse Treat 83:36-44
Marcus, Ruthanne; Makarenko, Iuliia; Mazhnaya, Alyona et al. (2017) Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug Alcohol Depend 179:213-219
Makarenko, Iuliia; Mazhnaya, Alyona; Marcus, Ruthanne et al. (2017) Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine. Int J Drug Policy 45:56-63

Showing the most recent 10 out of 35 publications